Journal of drugs in dermatology : JDD · 2023
Innate Error Immunities of the Th17 Immune Pathway Associated With Chronic Mucocutaneous Candidiasis: A Systematic Review.
Систематический обзорСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mirza Verda S, Zaino Mallory L, Feldman Steven R
Аннотация
BACKGROUND: Candida albicans is an opportunistic pathogenic yeast commensal in human mucosa. In individuals with compromised immune systems, it can present as chronic mucocutaneous candidiasis (CMC) or systemic infection. CMC often exists in the presence of other infectious phenotypes due to dysfunction of the Th17 immune response.
OBJECTIVE: To examine innate error immunities (IEI) of the Th17 immune response associated with CMC.
METHODS: MEDLINE PubMed, Embase, and Web of Science were searched for keywords and Medical Subject Headings (MeSH) related to the subject of interest. Nonapplicable and non-primary research methodologies were excluded.
RESULTS: We identified 266 articles; 89 were removed for being a duplicate, 108 for irrelevance, and 51 for being a review. We examined 18 studies, 5 on murine models, and 13 human studies.
CONCLUSION: Case reports in patients with CMC have identified a range of mutations in IL-17F, IL-17RA, IL-17RC, and ACT1. Mouse models confirm the role of IL-17A and IL-17F in disease susceptibility. J Drugs Dermatol. 2023;22(12):1197-1203. doi:10.36849/JDD.7579.
OBJECTIVE: To examine innate error immunities (IEI) of the Th17 immune response associated with CMC.
METHODS: MEDLINE PubMed, Embase, and Web of Science were searched for keywords and Medical Subject Headings (MeSH) related to the subject of interest. Nonapplicable and non-primary research methodologies were excluded.
RESULTS: We identified 266 articles; 89 were removed for being a duplicate, 108 for irrelevance, and 51 for being a review. We examined 18 studies, 5 on murine models, and 13 human studies.
CONCLUSION: Case reports in patients with CMC have identified a range of mutations in IL-17F, IL-17RA, IL-17RC, and ACT1. Mouse models confirm the role of IL-17A and IL-17F in disease susceptibility. J Drugs Dermatol. 2023;22(12):1197-1203. doi:10.36849/JDD.7579.